No one likes a reverse split, but it may be a necessary defence. The OR to DE move just adds clarity and makes future deals more agreeable and efficient. The name change may be the real tell in the cards being played.
I suspect CG did not get to be CEO without a strength for vision and a solid ego. His actions suggest that he believes enough to invest his own cash in their chances at the brass ring. As with all biotechs, the binary event will determine our success. The new name has many possible meanings, but the most applicable come from the bible and relates to a rising from the dead. Phoenix from the ashes, if you will. Something tells me that CG believes this vision can become a reality for AVI/Sarepta. He knows more than we do and is placing big bets on their success. I suspect the 36 week data is in-house and open for evaluation. If this data suggests a real clinical benefit, the brass ring gets closer. If not, they will have to wait on the 48 week data or force a deal to mitigate enterprize risk.
In poker terms, the stock has a downside risk of about 20-30 cents and an upside gain of $4-$6. Those are great pot odds, if you are getting in the game. If you have been in the game and your average pps is higher... Well, you can only hold or buy more to average down. 10 baggers don't come easy, but they will change your life.
Good luck to all longs and welcome any new players who like their chances.
when CG gets demoted it will look good
till then all fluff on up days
we need someone who the street trusts
this guy has lost it from the BOD's on down
make him trial head for duchenne and nothing else
You are off by a month. The trial started August 8 2011 or right around there. The 28 week data was collected Feb 7th or so. I believe even Chis mentioned lmid July as a time when the data will have been taken But you just have to go back to the start date of August 8th and subtrack 4 weeks. So I figure July 15th. But wilton said "a year - 52 week data" so they ay have added a month. Getting you to August 15th at the latest. Then add your 56 weeks for data compilation and you've got the presentation in Australia at World Muscle on the 10th of October. Someone here likes to use 10 ids to make this board interesting by creating non-issues. It ruins the board for sincere investors but there's nothing we can do. She's like the mental case in Full Metal Jacket.
By my count, the 24 week endpoint was achieved on or around Feb 29-March 2. It took a month to get the top line data ready for the April 2 call. The ANN presentation was on April 22. Count the weeks from March 2 forward... My calendar says August 17 completes the 48th week. (+/-1 week for the end dates) Assuming it takes 6-7 weeks to evaluate the data, as before. Report in early October. I believe this target was mentioned on their last call.
Note: Not trying to pump, lie or deceive. Just doing math on a standard calendar. If you get different dates, please share them and stop the name calling.
48 weeks is the next target for reporting. Previous calls set that report at early October. 36 week data was mentioned, but may not be reported. This data may inform or set the tone for their FDA discussions on P3 design and or alternative markers.